In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

European Journal of Immunology

Volumn 39, Issue 9, 2009, Pages 2424-2436

  Murillo, Oihana ^a   Dubrot, Juan ^a   Palazón, Asís ^a   Arina, Ainhoa ^a   Azpilikueta, Arantza ^a   Alfaro, Carlos ^a   Solano, Sarai ^a   Ochoa, María C ^a   Berasain, Carmen ^a   Gabari, Izaskun ^a   Pérez Gracia, José L ^b   Berraondo, Pedro ^a   Hervás Stubbs, Sandra ^a   Melero, Ignacio ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

CD137 (4 1BB); Cross priming; CTL; DC; Tumor immunity

Indexed keywords

CD137 MONOCLONAL ANTIBODY; COMPLEMENTARY DNA; DIPHTHERIA TOXIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CD137 ANTIGEN; OVA 8; OVA-8; OVALBUMIN; PEPTIDE FRAGMENT; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IN VIVO STUDY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOMA; TUMOR CELL; TUMOR IMMUNITY; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; DRUG POTENTIATION; IMMUNOLOGY; NEOPLASM; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIGENS, CD137; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CROSS-PRIMING; DENDRITIC CELLS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; OVALBUMIN; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 70349243743     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200838958     Document Type: Article

References (64)

1. Croft, M., Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 2003. 3: 609-620.
2. Watts, T. H., TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 2005. 23: 23-68.
3. Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellstrom, K. E., Mittler, R. S. and Chen, L., Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 1997. 3: 682-685.
4. Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E. et al., Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 2002. 109: 651-659.
5. Hurtado, J. C., Kim, Y. J. and Kwon, B. S., Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation- induced cell death. J. Immunol. 1997. 158: 2600-2609.
6. Wilcox, R. A., Tamada, K., Flies, D. B., Zhu, G., Chapoval, A. I., Blazar, B. R., Kast, W. M. and Chen, L., Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood 2004. 103: 177-184. (Pubitemid 38029936)
7. May, K. F., jr., Chen, L., Zheng, P. and Liu, Y., Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 2002. 62: 3459-3465. (Pubitemid 34651393)
8. Zhu, Y., Zhu, G., Luo, L., Flies, A. S. and Chen, L., CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 2007. 109: 4882-4889. (Pubitemid 46827785)
9. Pulle, G., Vidric, M. and Watts, T. H., IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J. Immunol. 2006. 176: 2739-2748. (Pubitemid 43306932)
10. Myers, L., Lee, S. W., Rossi, R. J., Lefrancois, L., Kwon, B. S., Mittler, R. S., Croft, M. and Vella, A. T., Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int. Immunol. 2006. 18: 325-333.
11. Melero, I., Johnston, J. V., Shufford, W. W., Mittler, R. S. and Chen, L., NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell. Immunol. 1998. 190: 167-172.
12. Lee, S. W., Park, Y., So, T., Kwon, B. S., Cheroutre, H., Mittler, R. S. and Croft, M., Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells. Nat. Immunol. 2008. 9: 917-926.
13. Melero, I., Murillo, O., Dubrot, J., Hervas-Stubbs, S. and Perez-Gracia, J. L., Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol. Sci. 2008. 29: 383-390.
14. Wilcox, R. A., Chapoval, A. I., Gorski, K. S., Otsuji, M., Shin, T., Flies, D. B., Tamada, K. et al., Cutting edge: expression of functional CD137 receptor by dendritic cells. J. Immunol. 2002. 168: 4262-4267. (Pubitemid 34441322)
15. Seaman, S., Stevens, J., Yang, M. Y., Logsdon, D., Graff-Cherry, C. and St Croix, B., Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007. 11: 539-554.
16. Murillo, O., Arina, A., Hervas-Stubbs, S., Gupta, A., McCluskey, B., Dubrot, J., Palazon, A. et al., Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin. Cancer Res. 2008. 14: 6895-6906.
17. Ochsenbein, A. F., Klenerman, P., Karrer, U., Ludewig, B., Pericin, M., Hengartner, H. and Zinkernagel, R. M., Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci USA 1999. 96: 2233-2238.
18. Heath, W. R. and Carbone, F. R., Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 2001. 19: 47-64.
19. Heath, W. R., Belz, G. T., Behrens, G. M., Smith, C. M., Forehan, S. P., Parish, I. A., Davey, G. M. et al., Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 2004. 199: 9-26.
20. Zinkernagel, R. M., On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol. 2002. 32: 2385-2392.
21. Melief, C. J., Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur. J. Immunol. 2003. 33: 2645-2654.
22. Wolkers, M. C., Stoetter, G., Vyth-Dreese, F. A. and Schumacher, T. N., Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses. J. Immunol. 2001. 167: 3577-3584. (Pubitemid 32910799)
23. van Mierlo, G. J., Boonman, Z. F., Dumortier, H. M., den Boer, A. T., Fransen, M. F., Nouta, J., van der Voort, E. I. et al., Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J. Immunol. 2004. 173: 6753-6759. (Pubitemid 39541061)
24. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D. and Levitsky, H., Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994. 264: 961-965. (Pubitemid 24196166)
25. Thomas, A. M., Santarsiero, L. M., Lutz, E. R., Armstrong, T. D., Chen, Y. C., Huang, L. Q., Laheru, D. A. et al., Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 2004. 200: 297-306.
26. Albert, M. L., Sauter, B. and Bhardwaj, N., Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998. 392: 86-89. (Pubitemid 28150594)
27. den Haan, J. M., Lehar, S. M. and Bevan, M. J., CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 2000. 192: 1685-1696.
28. Pooley, J. L., Heath, W. R. and Shortman, K., Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J. Immunol. 2001. 166: 5327-5330. (Pubitemid 32374150)
29. den Haan, J. M. and Bevan, M. J., Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J. Exp. Med. 2002. 196: 817-827.
30. Iyoda, T., Shimoyama, S., Liu, K., Omatsu, Y., Akiyama, Y., Maeda, Y., Takahara, K. et al., The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 2002. 195: 1289-1302.
31. Huarte, E., Tirapu, I., Arina, A., Vera, M., Alfaro, C., Murillo, O., Palencia, B. et al., Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. Expert Opin. Biol. Ther. 2005. 5: 7-22.
32. Sancho, D., Joffre, O. P., Keller, A. M., Rogers, N. C., Martinez, D., Hernanz- Falcon, P., Rosewell, I. and CR, E. S., Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 2009. 458: 899-903.
33. Brossart, P., Goldrath, A. W., Butz, E. A., Martin, S. and Bevan, M. J., Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 1997. 158: 3270-3276. (Pubitemid 127484043)
34. Choi, B. K., Kim, Y. H., Kang, W. J., Lee, S. K., Kim, K. H., Shin, S. M., Yokoyama, W. M. et al., Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res. 2007. 67: 8891-8899.
35. Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J. and Carbone, F. R., T cell receptor antagonist peptides induce positive selection. Cell 1994. 76: 17-27. (Pubitemid 24035278)
36. Zinkernagel, R. M., Ehl, S., Aichele, P., Oehen, S., Kundig, T. and Hengartner, H., Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev. 1997. 156: 199-209.
37. Goodnow, C. C., Chance encounters and organized rendezvous. Immunol. Rev. 1997. 156: 5-10.
38. Ochsenbein, A. F., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, J., Hemmi, S. et al., Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001. 411: 1058-1064. (Pubitemid 32612331)
39. Sotomayor, E. M., Borrello, I., Rattis, F. M., Cuenca, A. G., Abrams, J., Staveley-O'Carroll, K. and Levitsky, H. I., Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 2001. 98: 1070-1077.
40. Villadangos, J. A. and Schnorrer, P., Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol. 2007. 7: 543-555.
41. Lin, M. L., Zhan, Y., Proietto, A. I., Prato, S., Wu, L., Heath, W. R., Villadangos, J. A. and Lew, A. M., Selective suicide of cross-presenting CD8+ dendritic cells by cytochrome c injection shows functional heterogeneity within this subset. Proc. Natl. Acad. Sci. USA 2008. 105: 3029-3034.
42. Jung, S., Unutmaz, D., Wong, P., Sano, G., De los Santos, K., Sparwasser, T., Wu, S. et al., In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 2002. 17: 211-220.
43. Zaft, T., Sapoznikov, A., Krauthgamer, R., Littman, D. R. and Jung, S., CD11chigh dendritic cell ablation impairs lymphopenia-driven proliferation of naive and memory CD8+ T cells. J. Immunol. 2005. 175: 6428-6435. (Pubitemid 41598883)
44. Choi, B. K., Kim, Y. H., Kwon, P. M., Lee, S. C., Kang, S. W., Kim, M. S., Lee, M. J. and Kwon, B. S., 4-1BB functions as a survival factor in dendritic cells. J. Immunol. 2009. 182: 4107-4115.
45. Seo, S. K., Choi, J. H., Kim, Y. H., Kang, W. J., Park, H. Y., Suh, J. H., Choi, B. K. et al., 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 2004. 10: 1088-1094.
46. Murillo, O., Arina, A., Tirapu, I., Alfaro, C., Mazzolini, G., Palencia, B., Lopez-Diaz De Cerio, A. et al., Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin. Cancer Res. 2003. 9: 5454-5464.
47. Zhou, F., Rouse, B. T. and Huang, L., Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study. Cancer Res. 1992. 52: 6287-6291.
48. Curtsinger, J. M., Gerner, M. Y., Lins, D. C. and Mescher, M. F., Signal 3 availability limits the CD8 T cell response to a solid tumor. J. Immunol. 2007. 178: 6752-6760.
49. Nelson, D. J., Mukherjee, S., Bundell, C., Fisher, S., van Hagen, D. and Robinson, B., Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J. Immunol. 2001. 166: 5557-5566.
50. Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., Flament, C. et al., Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 2001. 7: 297-303.
51. Nguyen, L. T., Elford, A. R., Murakami, K., Garza, K. M., Schoenberger, S. P., Odermatt, B., Speiser, D. E. and Ohashi, P. S., Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 2002. 195: 423-435.
52. Zou, W., Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005. 5: 263-274.
53. Melero, I., Bach, N., Hellstrom, K. E., Aruffo, A., Mittler, R. S. and Chen, L., Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol. 1998. 28: 1116-1121.
54. Hoeffel, G., Ripoche, A. C., Matheoud, D., Nascimbeni, M., Escriou, N., Lebon, P., Heshmati, F. et al., Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity 2007. 27: 481-492. (Pubitemid 47418679)
55. Bennett, C. L. and Clausen, B. E., DC ablation in mice: promises, pitfalls, and challenges. Trends Immunol. 2007. 28: 525-531.
56. Hochweller, K., Striegler, J., Hammerling, G. J. and Garbi, N., A novel CD11c. DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur. J. Immunol. 2008. 38: 2776-2783.
57. Uno, T., Takeda, K., Kojima, Y., Yoshizawa, H., Akiba, H., Mittler, R. S., Gejyo, F. et al., Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 2006. 12: 693-698.
58. Teng, M. W., Westwood, J. A., Darcy, P. K., Sharkey, J., Tsuji, M., Franck, R. W., Porcelli, S. A. et al., Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res. 2007. 67: 7495-7504. (Pubitemid 47206579)
59. Melero, I., Arina, A., Murillo, O., Dubrot, J., Alfaro, C., Perez-Gracia, J. L., Bendandi, M. and Hervas-Stubbs, S., Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena. Clin. Cancer Res. 2006. 12: 2385-2389.
60. Apetoh, L., Tesniere, A., Ghiringhelli, F., Kroemer, G. and Zitvogel, L., Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008. 68: 4026-4030.
61. Ito, F., Li, Q., Shreiner, A. B., Okuyama, R., Jure-Kunkel, M. N., Teitz- Tennenbaum, S. and Chang, A. E., Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 2004. 64: 8411-8419. (Pubitemid 39491781)
62. Li, B., Lin, J., Vanroey, M., Jure-Kunkel, M. and Jooss, K., Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin. Immunol. 2007. 125: 76-87.
63. Tirapu, I., Arina, A., Mazzolini, G., Duarte, M., Alfaro, C., Feijoo, E., Qian, C. et al., Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int. J. Cancer 2004. 110: 51-60. (Pubitemid 38507203)
64. Chen, S. H., Pham-Nguyen, K. B., Martinet, O., Huang, Y., Yang, W., Thung, S. N., Chen, L. et al., Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol. Ther. 2000. 2: 39-46.